The study evaluated the efficacy and safety of using the MiniMed 640G system with SmartGuard technology (stopping insulin before an episode of hypoglycemia) compared with insulin pump therapy without a continuous glucose monitoring (CGM) system in adult patients with type 1 diabetes.
The study involved 153 adult patients with type 1 diabetes with more than 10 years of experience. All participants had episodes of severe hypoglycemia in the last 12 months. The study was conducted for 6 months in 5 countries (Great Britain, Holland, France, Canada and Italy).
WHAT IS SMARTGUARD TECHNOLOGY?
The MiniMed 640G System dramatically improves diabetes management with hypoglycemia prevention technology and personalized features that make life with diabetes easier.
HOW IT WORKS?
- SmartGuard technology can predict an episode of hypoglycemia up to 30 minutes before it occurs and automatically suspend insulin delivery.
- Once your glucose levels stabilize, SmartGuard will automatically resume insulin delivery.
- For better diabetes management, the pump user can set multiple low glucose thresholds based on the time of day.
Findings from the Smile study demonstrate that the use of the MiniMed 640G system with SmartGuard technology (stopping insulin delivery before an episode of hypoglycemia) can significantly reduce the incidence of episodes of hypoglycemia in adults with type 1 diabetes, compared with the use of an insulin pump without LMWH. At the same time, the level of HbA1c remains within the normal range.